Akari Therapeutics has announced the acceptance of its abstract for the ASCO Annual Meeting 2026, detailing the combination synergy of its spliceosome modulator antibody-drug conjugate (ADC), AKTX-101, with a K-Ras inhibitor in treating KRAS-mutated pancreatic cancers. This marks a pivotal moment for Akari as it advances AKTX-101 into Phase 1 clinical development, expected to commence by late 2026 or early 2027. The abstract emphasizes the potential of targeting RNA splicing as a novel therapeutic strategy in oncology.

The significance of these findings lies in the PH1 payload, a spliceosome modulator that disrupts RNA splicing within cancer cells, leading to cell death and immune activation. Preclinical studies have shown that AKTX-101 exhibits superior activity and prolonged survival compared to traditional ADCs that utilize microtubule inhibitors and DNA-damaging agents. Furthermore, the data suggest that AKTX-101 could be synergistic with checkpoint inhibitors, enhancing its therapeutic efficacy in a challenging subset of cancers characterized by KRAS mutations.

The implications for the field are substantial, as this research could shift the current paradigms in cancer drug development, particularly for tumors with difficult-to-target oncogenic drivers. The ability of AKTX-101 to engage the immune system while targeting specific cancer cell pathways may accelerate the timeline for developing effective treatments for KRAS-mutated cancers, a category that has historically posed significant challenges. As Akari moves forward with IND-enabling studies, the potential for RNA splicing modulation to become a cornerstone of targeted cancer therapy is increasingly tangible.

Source: globenewswire.com